




Mouse Anti-Feline CD8

Cat. No.	Format	Size
8120-01	Purified (UNLB)	0.5 mg
8120-02	Fluorescein (FITC)	0.5 mg
8120-08	Biotin (BIOT)	0.5 mg
8120-09	R-phycoerythrin (PE)	0.1 mg



Feline peripheral blood lymphocytes were stained with Mouse Anti-Feline CD8-PE (SB Cat. No. 8120-09) and Mouse Anti-Feline CD4-FITC (SB Cat. No. 8130-02).

Overview

Clone	fCD8 (FT2)
Isotype	Mouse (CAF1) IgG ₁ κ
Immunogen	Feline thymocytes
Specificity	Feline/Lion/Tsushima Leopard Cat CD8β; Mr 31 & 38 kDa
Alternate Name(s)	fCD8

Description

Feline CD8, a member of the immunoglobulin superfamily of cell surface receptors, is a type II transmembrane glycoprotein that is expressed as a heterodimer on the suppressor/cytotoxic subpopulation of peripheral T lymphocytes. It is present on approximately 76% of thymocytes, 14% of splenocytes, 1% of bone marrow cells, and 15% of peripheral blood lymphocytes. CD8 functions as a co-receptor with MHC Class I-restricted T cell receptors in antigen recognition.

Applications

FC – Quality tested^{1,5-23}
 IHC-FS – Reported in literature^{2,3}
 ICC – Reported in literature¹
 IP – Reported in literature¹
 Sep – Reported in literature⁴

Working Dilutions

Flow Cytometry	FITC and BIOT conjugates	≤ 1 μg/10 ⁶ cells
	PE conjugate	≤ 0.2 μg/10 ⁶ cells
For flow cytometry, the suggested use of these reagents is in a final volume of 100 μL		

Other Applications Since applications vary, you should determine the optimum working dilution for the product that is appropriate for your specific need.

For Research Use Only. Not for Diagnostic or Therapeutic Use.

Corporate Offices: 160 Oxmoor Blvd • Birmingham, AL 35209 • USA Mailing Address: P.O. Box 26221 • Birmingham, AL 35260 • USA

Tel: 205.945.1774 • U.S. and Canada: 800.722.2255 • Fax: 205.945.8768

Email: info@southernbiotech.com • Website: www.southernbiotech.com

Handling and Storage

- The purified (UNLB) antibody is supplied as 0.5 mg of purified immunoglobulin in 1.0 mL of borate buffered saline, pH 8.2. *No preservatives or amine-containing buffer salts added.* Store at 2-8°C.
- The fluorescein (FITC) conjugate is supplied as 0.5 mg in 1.0 mL of PBS/NaN₃. Store at 2-8°C.
- The biotin (BIOT) conjugate is supplied as 0.5 mg in 1.0 mL of PBS/NaN₃. Store at 2-8°C.
- The R-phycoerythrin (PE) conjugate is supplied as 0.1 mg in 1.0 mL of PBS/NaN₃ and a stabilizing agent. Store at 2-8°C. **Do not freeze!**
- Protect fluorochrome-conjugated forms from light. Reagents are stable for the period shown on the label if stored as directed.

Warning

Some reagents contain sodium azide. Please refer to product specific (M)SDS.

References

1. Klotz FW, Cooper MD. A feline thymocyte antigen defined by a monoclonal antibody (FT2) identifies a subpopulation of non-helper cells capable of specific cytotoxicity. *J Immunol.* 1986;136:2510-4. (Immunogen, FC, ICC, IP)
2. Rideout BA, Lowenstine LJ, Hutson CA, Moore PF, Pedersen NC. Characterization of morphologic changes and lymphocyte subset distribution in lymph nodes from cats with naturally acquired feline immunodeficiency virus infection. *Vet Pathol.* 1992;29:391-9. (IHC-FS)
3. Femenia F, Crespeau F, Fontaine JJ, Boucheix C, Parodi AL. Early haematological and pathological abnormalities of pathogen-free cats experimentally infected with feline immunodeficiency virus (FIV). *Vet Res.* 1994;25:544-54. (IHC-FS, FC)
4. Choi I, Hokanson R, Collisson EW. Anti-feline immunodeficiency virus (FIV) soluble factor(s) produced from antigen-stimulated feline CD8⁺ T lymphocytes suppresses FIV replication. *J Virol.* 2000;74:676-83. (Sep)
5. Nishimura Y, Goto Y, Yoneda K, Endo Y, Mizuno T, Hamachi M, et al. Interspecies transmission of feline immunodeficiency virus from the domestic cat to the Tsushima cat (*Felis bengalensis euphilura*) in the wild. *J Virol.* 1999;73:7916-21. (FC, Tsushima Reactivity)
6. Hohdatsu T, Hirabayashi H, Motokawa K, Koyama H. Comparative study of the cell tropism of feline immunodeficiency virus isolates of subtypes A, B and D classified on the basis of the env gene V3-V5 sequence. *J Gen Virol.* 1996;77:93-100. (FC)
7. Dean GA, Reubel GH, Moore PF, Pedersen NC. Proviral burden and infection kinetics of feline immunodeficiency virus in lymphocyte subsets of blood and lymph node. *J Virol.* 1996;70:5165-9. (FC)
8. Shimojima M, Miyazawa T, Kohmoto M, Ikeda Y, Nishimura Y, Maeda K, et al. Expansion of CD8 α + β - cells in cats infected with feline immunodeficiency virus. *J Gen Virol.* 1998;79:91-4. (FC)
9. Barr MC, Billaud J, Selway DR, Huitron-Resendiz S, Osborn KG, Henriksen SJ, et al. Effects of multiple acute morphine exposures on feline immunodeficiency virus disease progression. *J Infect Dis.* 2000;182:725-32. (FC)
10. Phipps AJ, Hayes KA, Buck WR, Podell M, Mathes LE. Neurophysiologic and immunologic abnormalities associated with feline immunodeficiency virus molecular clone FIV-PPR DNA inoculation. *J Acquir Immune Defic Syndr.* 2000;23:8-16. (FC)
11. Hokanson RM, TerWee J, Choi I, Coates J, Dean H, Reddy DN, et al. Dose response studies of acute feline immunodeficiency virus PPR strain infection in cats. *Vet Microbiol.* 2000;76:311-27. (FC)
12. Barr MC, Huitron-Resendiz S, Selway DR, Henriksen SJ, Phillips TR. Exogenous glucocorticoids alter parameters of early feline immunodeficiency virus infection. *J Infect Dis.* 2000;181:576-86. (FC)
13. Hohdatsu T, Yamazaki A, Yamada M, Kusuhara H, Kaneshima T, Koyama H. Ability of CD8⁺ T cell anti-feline immunodeficiency virus activity correlated with peripheral CD4⁺ T cell counts and plasma viremia. *Microbiol Immunol.* 2003;47:765-73. (FC)
14. de Groot-Mijnes JD, van Dun JM, van der Most RG, de Groot R. Natural history of a recurrent feline coronavirus infection and the role of cellular immunity in survival and disease. *J Virol.* 2005;79:1036-44. (FC)
15. Broche-Pierre S, Richardson J, Moraillon A, Sonigo P. Evaluation of live feline immunodeficiency virus vaccines with modified antigenic properties. *J Gen Virol.* 2005;86:2495-506. (FC)
16. El Garch H, Richard S, Piras F, Leard T, Poulet H, Andreoni C, et al. Feline leukemia virus (FeLV)-specific IFN γ + T-cell responses are induced in cats following transdermal vaccination with a recombinant FeLV vaccine. *Int J Appl Res Vet Med.* 2006;4:100-8. (FC)
17. Brennan G, Podell MD, Wack R, Kraft S, Troyer JL, Bielefeldt-Ohmann H, et al. Neurologic disease in captive lions (*Panthera leo*) with low-titer lion lentivirus infection. *J Clin Microbiol.* 2006;44:4345-52. (FC, Lion Reactivity)
18. Dean GA, LaVoy A, Yearley J, Stanton C. Cytokine modulation of the innate immune response in feline immunodeficiency virus-infected cats. *J Infect Dis.* 2006;193:1520-7. (FC)
19. Pepin AC, Tandon R, Cattori V, Niederer E, Riond B, Willi B, et al. Cellular segregation of feline leukemia provirus and viral RNA in leukocyte subsets of long-term experimentally infected cats. *Virus Res.* 2007;127:9-16. (FC)
20. Maksiarekul S, Dubie RA, Shen X, Kieu H, Dean GA, Sparger EE. Vaccination with vif-deleted feline immunodeficiency virus provirus, GM-CSF, and TNF- α plasmids preserves global CD4 T lymphocyte function after challenge with FIV. *Vaccine.* 2009;27:3754-65. (FC)
21. Thompson J, MacMillan M, Boegler K, Wood C, Elder JH, VandeWoude S. Pathogenicity and rapid growth kinetics of feline immunodeficiency virus are linked to 3' elements. *PLoS One.* 2011;6(8):e24020. (FC)
22. Novacco M, Boretti FS, Franchini M, Riond B, Meli ML, Hofmann-Lehmann R. Protection from reinfection in "Candidatus *Mycoplasma turicensis*"-infected cats and characterization of the immune response. *Vet Res.* 2012;43:82. (FC)
23. Hicks CA, Willi B, Riond B, Novacco M, Meli ML, Stokes CR, et al. Protective Immunity against Infection with *Mycoplasma haemofelis*. *Clin Vaccine Immunol.* 2015;22:108-18. (FC)